Why is therapy with rasagiline recommended before levodopa to start treatment in patients with Parkinson’s disease?

Rasagiline is an irreversible, selective, second generation MAO-B inhibitor. It’s efficacy in monotherapy in early Parkinson’s disease (PD) was well established in the clinical trials, although its symptomatic effects are typically mild. Earlier initiation of rasagiline treatment is associated with improved long-term outcomes compared with delayed therapy. Recent studies have indicated that rasagiline may be neuroprotective, but the neuroproective features of rasagiline weren’t unambiguously proved. Rasagiline has a relevant place in early PD treatment.